Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange

Blood Purification

Volumn 18, Issue 2, 2000, Pages 115-120

  Tesař, Vladimír ^a   Jelinkova E ^a   Jirsa Jr , M ^a   Bakosova M ^a   Pitha P ^a   Chabova V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adhesion molecules; Cytokines; Myasthenia gravis; Plasma exchange

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; MYASTHENIA GRAVIS; PATHOGENESIS; PLASMA VOLUME; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0343090804     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000014434     Document Type: Article

References (27)

1. Drachman DB: Myasthenia gravis. N Engl J Med 1994;330:1797.
2. Drachman DB, Adams RN, Josifek LF, et al: Functional activities of antibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982;307: 769.
3. Yi Q, Ahlberg R, Pirskanen R, et al: Acetylcholine receptor-reactive T cells in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper cells. J Neuroimmunol 1994;50:177-186.
4. Link J, Soderstrom M, Ljungdahl A, et al: Organ-specific autoantibodies induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology 1994;44: 728-734.
5. Yi Q, Lefvert AK: Idiotype-and anti-idiotype-reactive T lymphocytes in myasthenia gravis. Evidence for the involvement of different subpopulations of T helper lymphocytes. J Immunol 1994;153:3353-3359.
6. Yi Q, Pirskanen R, Lefvert AK: Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J Neuroimmunol 1993;42:215.
7. Link J, Fredrikson S, Soderstrom M, et al: Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Ann Neurol 1994;35:197-203.
8. Shimada K, Koh CS, Yanagisawa N: Detection of interleukin-6 in serum and cerebrospinal fluid of patients with neuroimmunological diseases (in Japanese). Arerugi 1993;42:934-940.
9. Confalonieri P, Antozzi C, Cornelio F, et al: Immune activation in myasthenia gravis: Soluble interleukin-2 receptor, interferon-gamma and tumor necrosis factor-alpha levels in patient's serum. J Neuroimmunol 1993;48:33-36.
10. Sanders DB, Scoppetta C: The treatment of patients with myasthenia gravis. Neurology 1990;40:1828.
11. Dau PC, Lindstrom JM, Cassel CK, et al: Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297:1134.
12. Engel AG: Disorders of neuromuscular transmission; in Wyngaarden JB, Smith LH, Bennett JC (eds): Cecil Textbook of Medicine, ed 19. Philadelphia, Saunders, 1992, pp 2265-2268.
13. Tesař V, Jelínková E, Mašek Z, et al: Influence of plasma exchange on serum levels of cytokines and adhesion molecules in ANCA-positive renal vasculitis. Blood Purif 1998;16:72-80.
14. Brooks EB, Pachner AR, Drachman DB, et al: A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in 'antibody negative' myasthenia gravis. J Neuroimmunol 1990;28: 83.
15. Willcox N, Baggi F, Batocchi AP, et al: Approaches for studying the pathogenic T cells in autoimmune patients. Ann NY Acad Sci 1993; 681:219-237.
16. Kirchner T, Hoppe F, Schalke B, et al: Microenvironment of thymic myoid cells in myasthenia gravis. Virchows Arch Cell Pathol 1988; 54:295.
17. Asthana D, Fujii Y, Huston GE, et al: Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin Immunol Immunopathol 1993;67:240-248.
18. Aderka D: The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-240.
19. Cohen-Kaminsky S, Delattre RM, Devergne O, et al: High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis. Ann NY Acad Sci 1993;681:97-99.
20. Cohen-Kaminsky S, Devergne O, Delattre RM, et al: Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur Cytokine Netw 1993;4:121-132.
21. Bansal AS, Ollier W, Marsh MN, et al: Variations in serum CD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 1993;68:285-289.
22. Stegmayr BG: Plasmapheresis in severe sepsis or septic shock. Blood Purif 1996;14:94-101.
23. Bellomo R, Tipping P, Boyce N: Tumor necrosis factor clearances during veno-venous hemodiafiltration in the critically ill. ASAIO J 1992;37:322-323.
24. Cottrell AC, Mehta RL: Cytokine kinetics in septic ARF patients on continuous veno-veno hemodialysis. J Am Soc Nephrol 1992;3:279.
25. Kaplan AA: Extracorporeal blood purification in the treatment of acute renal failure with multiorgan involvement. Blood Purif 1996;14:86-93.
26. Ronco C: Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 1993;40: 187-198.
27. Byrick RJ, Goldstein MB, Wong PY: Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis. Crit Care Med 1992;20:1483-1486.